Thyora Therapeutics Launches to Build a Next-Generation Platform for Covalent Drug Discovery
New biotechnology company emerges from breakthrough science published in Science with an integrated platform designed to advance a new generation of precision covalent medicines
Thyora Therapeutics today emerged from stealth as a biotechnology company leveraging next-generation covalent chemistry, with a mission to accelerate clinical translation and create therapies for high-unmet medical needs. Founded on breakthrough discoveries published today in Scienceby scientists at Moffitt Cancer Center, the company is advancing an integrated platform that combines novel covalent chemistry with AI-enabled chemoproteomics to unlock a new generation of precision therapeutics.
Thyora was co-founded by Justin M. Lopchuk, Ph.D., Andrii Monastyrskyi, Ph.D., and Derek Duckett, Ph.D., inventors of the company’s foundational technologies, together with biotechnology executive T.J. Langer, who serves as Chief Executive Officer. Together, the founders established Thyora to translate pioneering science into transformative medicines by integrating world-class chemistry, pharmacology and drug discovery expertise.
“When I first saw the science, I believed it represented one of those rare opportunities to build a company around discoveries that could fundamentally change an entire field,” said T.J. Langer, Chief Executive Officer of Thyora Therapeutics. “The team has developed technologies with the potential to reshape how covalent medicines are discovered and developed and to reach disease targets long considered undruggable. We founded Thyora to bring those discoveries out of the laboratory and build a company capable of translating extraordinary science into transformative medicines for patients.”
